100 related articles for article (PubMed ID: 8438092)
1. Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075).
Spiegel JF; Spear MA; Brown JM
Radiother Oncol; 1993 Jan; 26(1):79-81. PubMed ID: 8438092
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
Shulman LN; Buswell L; Riese N; Doherty N; Loeffler JS; von Roemeling RW; Coleman CN
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):349-53. PubMed ID: 10760430
[TBL] [Abstract][Full Text] [Related]
3. Assessment of micronucleus induction in SCCVII cells treated with bioreductive agents, WIN 59075 (SR 4233) and mitomycin C, under aerobic and hypoxic conditions.
Shibata T; Shibamoto Y; Sasai K; Oya N; Takagi T; Murata R; Abe M
Mutat Res; 1995 Apr; 342(3-4):171-7. PubMed ID: 7715618
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
Adam M; Ottenjann S; Künzel G; Busch R; Erhardt W; Nieder C; Molls M
Strahlenther Onkol; 2006 Apr; 182(4):231-9. PubMed ID: 16622625
[TBL] [Abstract][Full Text] [Related]
5. The in situ tumour response to combinations of cyclophosphamide and tirapazamine.
Siemann DW
Br J Cancer Suppl; 1996 Jul; 27():S65-9. PubMed ID: 8763849
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
Le QT; McCoy J; Williamson S; Ryu J; Gaspar LE; Edelman MJ; Dakhil SR; Sides SD; Crowley JJ; Gandara DR;
Clin Cancer Res; 2004 Aug; 10(16):5418-24. PubMed ID: 15328179
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
9. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation.
Doherty N; Hancock SL; Kaye S; Coleman CN; Shulman L; Marquez C; Mariscal C; Rampling R; Senan S; Roemeling RV
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):379-82. PubMed ID: 8195037
[TBL] [Abstract][Full Text] [Related]
10. Acute lesions in rats caused by 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) or nitromin: a comparison with rates of reduction in microsomal systems from target organs.
White IN; Cahill A; Davies A; Carthew P
Arch Toxicol; 1992; 66(2):100-6. PubMed ID: 1605723
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie MJ; Brown JM
Cancer Res; 1993 Oct; 53(19):4633-6. PubMed ID: 8402639
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
Lee AE; Wilson WR
Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
el-Said A; Menke D; Dorie MJ; Brown JM
Radiat Oncol Investig; 1999; 7(3):163-9. PubMed ID: 10406058
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of oncogenicity for bioreductive drugs.
Hei TK; Piao CQ; He ZY; Hall EJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
[TBL] [Abstract][Full Text] [Related]
15. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts.
Wilder RB; McGann JK; Sutherland WR; Waller EK; Minchinton AI; Goris ML; Knox SJ
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):119-26. PubMed ID: 8270432
[TBL] [Abstract][Full Text] [Related]
16. Tirapazamine (SR 4233) interrupts cell cycle progression and induces apoptosis.
Lin PS; Ho KC; Yang SJ
Cancer Lett; 1996 Aug; 105(2):249-55. PubMed ID: 8697451
[TBL] [Abstract][Full Text] [Related]
17. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the bioreductive drug SR 4233 and photodynamic therapy using photofrin in a mouse tumor model.
Baas P; Oppelaar H; Stavenuiter M; van Zandwijk N; Stewart FA
Int J Radiat Oncol Biol Phys; 1993 Oct; 27(3):665-70. PubMed ID: 8226162
[TBL] [Abstract][Full Text] [Related]
19. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
20. Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice.
Cardinale RM; Dillehay LE; Williams JA; Tabassi K; Brem H; Lee DJ
Radiat Oncol Investig; 1998; 6(2):63-70. PubMed ID: 9572682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
